Transcutaneous Superior Laryngeal Nerve Stimulation to Upregulate Swallowing Frequency and Urge to Swallow in Patients Living With ALS

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorNova Southeastern University

About this trial

Prospective, single-arm pilot study evaluating transcutaneous electrical nerve stimulation of the superior laryngeal nerve (TENS-SLN) in individuals with ALS.

Up to 5 participants with confirmed ALS and bulbar involvement will be enrolled.

Primary outcomes: swallowing frequency and perceived urge to swallow. Participants complete a baseline visit, followed by two supervised treatment sessions within one week, and a final post-treatment evaluation.

Optional visits (up to 2) may be used to individualize stimulation parameters prior to treatment.

Swallowing function will be assessed using physiological monitoring, fiberoptic endoscopy, and videofluoroscopic swallow study (VFSS).

TENS-SLN is a non-invasive neuromodulation approach targeting sensory pathways to facilitate swallowing without inducing muscle contraction.

This pilot study is designed to assess feasibility, safety, and preliminary effect sizes to inform future randomized trials, and is not powered to determine efficacy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Confirmed diagnosis of ALS (El-Escorial Criteria)

ALS FRS Bulbar Subscore of ≤ 10 and ≥ 3.

Functional Oral Intake scale score ≥ 2

Disqualifiers

A diagnosis of significant cognitive impairment or frontotemporal dementia per the treating neurologist or neuropsychologist,

Current nasogastric tube placement

Current head and neck carcinoma

Pacemaker or implanted defibrillator or history of diagnosed arrhythmia, bradycardia, or repeated attacks of hypotension,

Trial design

Design model

Single group

Treatments tested in this trial

  • Transcutaneous Superior Laryngeal Nerve Stimulation to Upregulate Swallowing Frequency and Urge to Swallow

    Other intervention

    Transcutaneous Superior Laryngeal Nerve Stimulation to Upregulate Swallowing Frequency and Urge to Swallow in ALS

Treatment groups

5 Participants
are divided into 1 treatment group
Group A: Interventional GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Swallowing Frequency

The count of swallows per unit time with predefined epochs

Time frame
From enrollment to the end of the 7-day follow-up period
2

Urge-to-swallow

patient reported urge to swallow during rest and stimulation periods on a modified Borg scale, 0 (very easy) to 10 (very difficult to elicit a swallow)

Time frame
Measured from enrollment to the end of the 7 day follow up period

Secondary outcomes

1

Body weight gain/loss

The total body weight (lbs)

Time frame
At Day 1 and at Day 7
2

Maximum Expiratory Pressure

Maximum expiratory pressure achieved during forceful exhalation

Time frame
From enrollment to the end of the 7-day follow up period
3

Lingual pressure assessment

Maximum lingual pressure and saliva swallowing pressures will be obtained using the IOPI oral performance in 3 instances.

Time frame
At baseline (Day 1) pre-procedural, on Day 1 post-procedure, and on Day 7
4

Peak cough flow

Maximum expiratory flow achieved during the expulsive phase of the cough (PCF, L/min)

Time frame
One at enrollment and one at the end of the 7- day folow-up period

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Nova Southeastern University

Lead sponsor

Curators of the University of Missouri

Collaborator

This trial is not recruiting at the moment. You can still explore other options: